Amended Current Report Filing (8-k/a)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2022
CATALYST BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-51173 56-2020050
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
611 Gateway Blvd, Suite 710, South San Francisco, CA 94080
(Address of principal executive offices)
(650) 871-0761
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock CBIO Nasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Explanatory Note
On May 23, 2022, Catalyst Biosciences, Inc. (“Catalyst”) filed a Form 8-K with the Securities and Exchange Commission (the “Original Form 8-K”), reporting, among other items, that on May 19, 2022, Catalyst entered into and closed on an Asset Purchase Agreement with Vertex Pharmaceuticals Incorporated.
This Amendment No. 1 to the Original Form 8-K amends and supplements the Original Form 8-K solely to amend and restate Item 9.01 to the Original Form 8-K to file the pro forma financial information as Exhibit 99.2, to add Exhibit 99.2 to the exhibit list and to include a hyperlink to such Exhibit 99.2. Such pro forma financial information was inadvertently included in the Original Form 8-K as part of Exhibit 99.1 thereto.
Except as set forth herein, no modifications have been made to the information contained in the Original Form 8-K.
Item 9.01
Financial Statements and Exhibits.
(b) Pro Forma Financial Information
Catalyst’s unaudited pro forma condensed consolidated financial information is included as Exhibit 99.2 hereto and is incorporated by reference in this Item 9.01(b).
(d) Exhibits
Exhibit
No. Description
99.1 Press Release of Catalyst Biosciences, Inc. dated May 23, 2022 (incorporated by reference to Exhibit 99.1 to the Original Form 8-K filed on May 23, 2022).
99.2 Unaudited Pro Forma Condensed Consolidated Financial Statements of Catalyst Biosciences, Inc.
104 Cover Page Interactive Data File (formatted as Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CATALYST BIOSCIENCES, INC.
Date: May 23, 2022
/s/ Nassim Usman
Nassim Usman, Ph.D.
